Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, De Croze D, Meseure D, Salomon A, Laé M, Reyal F, Biganzoli E, Neven P, Desmedt C. Floris G, et al. Among authors: punie k. J Natl Cancer Inst. 2021 Feb 1;113(2):146-153. doi: 10.1093/jnci/djaa090. J Natl Cancer Inst. 2021. PMID: 33152071 Free PMC article.
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B. Loyson T, et al. Among authors: punie k. Acta Clin Belg. 2018 Apr;73(2):100-109. doi: 10.1080/17843286.2017.1348001. Epub 2017 Jul 10. Acta Clin Belg. 2018. PMID: 28693379
Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B. van Cann T, et al. Among authors: punie k. Support Care Cancer. 2018 Mar;26(3):869-878. doi: 10.1007/s00520-017-3903-5. Epub 2017 Sep 30. Support Care Cancer. 2018. PMID: 28963584
Breast cancer subtype and survival by parity and time since last birth.
De Mulder H, Laenen A, Wildiers H, Punie K, Poppe A, Remmerie C, Lefrère H, Nevelsteen I, Smeets A, Van Nieuwenhuysen E, Han S, Van Limbergen E, Floris G, Vergote I, Neven P. De Mulder H, et al. Among authors: punie k. Breast Cancer Res Treat. 2018 Jun;169(3):481-487. doi: 10.1007/s10549-018-4701-6. Epub 2018 Feb 10. Breast Cancer Res Treat. 2018. PMID: 29426984
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Hoste G, Punie K, Wildiers H, Beuselinck B, Lefever I, Van Nieuwenhuysen E, Han SN, Berteloot P, Concin N, Salihi R, Vergote I, Neven P. Hoste G, et al. Among authors: punie k. Breast Cancer Res Treat. 2018 Aug;171(1):131-141. doi: 10.1007/s10549-018-4827-6. Epub 2018 May 16. Breast Cancer Res Treat. 2018. PMID: 29766363
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Hoste G, Slembrouck L, Jongen L, Punie K, Matton T, Vander Borght S, Vanden Bempt I, Menten J, Wildiers H, Floris G, Arteaga C, Neven P. Hoste G, et al. Among authors: punie k. Clin Drug Investig. 2019 Jan;39(1):113. doi: 10.1007/s40261-019-00748-x. Clin Drug Investig. 2019. PMID: 30637612
105 results